XCancer

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

Description:

To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.

Sponsor:

MD Anderson Cancer Center

Phase:

Phase 1

Contacts:

Steven Lin, MD (CONTACT)

shlin@mdanderson.org

(713) 563-8490

Steven Lin, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT06414902 - Click here to see study on

ClinicalTrials.gov

AraG (ArabinoFuranosylGuanine)

Isotope(s):
Target(s):
  • Activated T-Cells
Ligand Class: Small Molecules

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules
Inclusion
  • Female participants of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical
  • 1. Participants must be ≥18 years of age
  • Ability to provide written informed consent in accordance with institutional policies
  • Participants with locally advanced esophageal cancer
  • Participants with untreated documented carcinoma of the esophagus that is \> 2 cm in patients who are going to receive systemic therapy concurrently with radiation as primary therapy are eligible
Exclusion
  • eGFR\<40 within 1 month prior to receiving 8F-FAraG
  • Pregnant or lactating females - Pregnant women are excluded from this study because 18F-FAraG PET agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with \[Agent\], breastfeeding should be discontinued if the mother is treated with \[Agent\]. These potential risks may also apply to other agents used in this study.
  • 1. Body weight ≥400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
  • History of allergic reaction to intravenous contrast